Direct tumor injection: new hope for advanced cancer patients?
NCT ID NCT03871348
Summary
This was an early-stage trial testing a new drug called SAR441000, which was injected directly into tumors. It aimed to find a safe dose and see if the drug, given alone or with another cancer therapy (cemiplimab), could help control advanced cancers in patients who had no other standard treatment options. The study was terminated and involved 77 participants with various advanced solid tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic - Cleveland- Site Number : 8400007
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute- Site Number : 8400003
Boston, Massachusetts, 02215, United States
-
Investigational Site Number : 0560001
Brussels, 1200, Belgium
-
Investigational Site Number : 0560002
Leuven, 3000, Belgium
-
Investigational Site Number : 0560003
Ghent, 9000, Belgium
-
Investigational Site Number : 2500001
Villejuif, 94805, France
-
Investigational Site Number : 2500002
Paris, 75010, France
-
Investigational Site Number : 2500004
Marseille, 13885, France
-
Investigational Site Number : 2760001
Mainz, 55131, Germany
-
Investigational Site Number : 2760003
Mannheim, 68167, Germany
-
Investigational Site Number : 2760004
Heidelberg, 69120, Germany
-
Investigational Site Number : 2760005
Hamburg, 20246, Germany
-
Investigational Site Number : 2760006
Tübingen, 72076, Germany
-
Investigational Site Number : 5280001
Rotterdam, 3015 CE, Netherlands
-
Investigational Site Number : 5280002
Nijmegen, 6525 GA, Netherlands
-
Investigational Site Number : 7240001
Pamplona, Navarre, 31008, Spain
-
Investigational Site Number : 7240002
Valencia, 46014, Spain
-
Investigational Site Number : 7240004
Barcelona, Catalunya [Cataluña], 08036, Spain
-
The University of Texas MD Anderson Cancer Center- Site Number : 8400002
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.